Literature DB >> 1155748

Pharmacokinetics of ketamine in man.

J Wieber, R Gugler, J H Hengstmann, H J Dengler.   

Abstract

A method for the analysis of ketamine and of its metabolites is described using gas-liquid chromatography for separation and flame ionization detection. The lower limit of detection for ketamine in serum was 0.025 mug/ml. The pharmacokinetic behaviour of ketamine after intravenous injection may be described in terms of an open two-compartment model. The serum half-life of ketamine was in alpha-phase about 11 min, the predominant half-life for the beta-phase 2.5 h. The half-life of ketamine and its metabolities in urine was comparable to that in serum. It could be shown that the duration of anaesthesia is not only correlated ti ist rapid metabolic breakdown and elimination, but also to the distribution of the drug peripheral tissue.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1155748

Source DB:  PubMed          Journal:  Anaesthesist        ISSN： 0003-2417            Impact factor:   1.041


  39 in total

Review 1.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

2.  A parallel chiral-achiral liquid chromatographic method for the determination of the stereoisomers of ketamine and ketamine metabolites in the plasma and urine of patients with complex regional pain syndrome.

Authors:  Ruin Moaddel; Swarajya Lakshmi Vattem Venkata; Mary J Tanga; James E Bupp; Carol E Green; Lalitha Iyer; Anna Furimsky; Michael E Goldberg; Marc C Torjman; Irving W Wainer
Journal:  Talanta       Date:  2010-08-13       Impact factor: 6.057

3.  Inhibition by anaesthetics of 14C-guanidinium flux through the voltage-gated sodium channel and the cation channel of the 5-HT3 receptor of N1E-115 neuroblastoma cells.

Authors:  M Barann; M Göthert; K Fink; H Bönisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-02       Impact factor: 3.000

4.  Pharmacokinetics of intravenous anaesthetics: implications for clinical use.

Authors:  M M Ghoneim; K Korttila
Journal:  Clin Pharmacokinet       Date:  1977 Sep-Oct       Impact factor: 6.447

Review 5.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

6.  Use of human microsomes and deuterated substrates: an alternative approach for the identification of novel metabolites of ketamine by mass spectrometry.

Authors:  Sophie C Turfus; Mark C Parkin; David A Cowan; John M Halket; Norman W Smith; Robin A Braithwaite; Simon P Elliot; Glyn B Steventon; Andrew T Kicman
Journal:  Drug Metab Dispos       Date:  2009-05-15       Impact factor: 3.922

7.  Continuous ketamine infusion for one-lung anaesthesia.

Authors:  A I Weinreich; G Silvay; P D Lumb
Journal:  Can Anaesth Soc J       Date:  1980-09

8.  Kinetics of nicotinic acetylcholine ion channels in the presence of intravenous anaesthetics and induction agents.

Authors:  R E Wachtel; E S Wegrzynowicz
Journal:  Br J Pharmacol       Date:  1992-07       Impact factor: 8.739

9.  The N-methyl-D-aspartate (NMDA) receptor antagonist dizocilpine (MK-801) suppresses enflurane-induced opisthotonus in mice.

Authors:  H Komatsu; J Nogaya; D Anabuki; K Ogli
Journal:  J Anesth       Date:  1993-10       Impact factor: 2.078

10.  Sedation and anesthesia options for pediatric patients in the radiation oncology suite.

Authors:  Eric A Harris
Journal:  Int J Pediatr       Date:  2010-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.